Anzeige
Mehr »
Dienstag, 25.11.2025 - Börsentäglich über 12.000 News
Goldrausch 2.0: 60% Insideranteil - warum dieser Gold-Explorer als Geheimtipp gilt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PJ4S | ISIN: DK0061123312 | Ticker-Symbol: 96X
Frankfurt
25.11.25 | 15:29
3,200 Euro
-0,62 % -0,020
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
FLUOGUIDE A/S Chart 1 Jahr
5-Tage-Chart
FLUOGUIDE A/S 5-Tage-Chart
ACCESS Newswire
164 Leser
Artikel bewerten:
(1)

Invitation to FluoGuide A/S Webcast on 27 November 2025

KØBENHAVN, DK / ACCESS Newswire / November 24, 2025 / FluoGuide A/S (STO:FLUO) - FluoGuide A/S will publish its Interim Report Q3 2025 on Thursday 27 November 2025.

The following event will take place later that day:

A live webcast for shareholders, analysts, investors and representatives of the media:

Topic: FluoGuide Operational and Financial Results for Q3 2025
Date: Thursday 27 November 2025
Time: 14.00 CET

The webcast is hosted by analyst Christian Binder, Redeye. FluoGuide is represented by CEO Morten Albrechtsen and CFO Ole Larsen.

Please login to the webcast via the following link: https://www.redeye.se/events/1127356/live-q-fluoguide-2

Questions can be sent in advance by email to Christian Binder (christian.binder@redeye.se) or can be raised at the question session during the webcast.

A recorded version of the presentation will be available on the website after the webcast has concluded.

For further information, please contact:
Morten Albrechtsen, CEO
FluoGuide A/S
Phone: +45 24 25 62 66
E-mail: ma@fluoguide.com

Follow FluoGuide on linkedIn
Follow FluoGuide on LinkedIn: https://www.linkedin.com/company/fluoguide/

Sign up to receive FluoGuide news
Sign up to receive FluoGuide news: https://fluoguide.com/investor/email-alerts/

About FluoGuide
FluoGuide lights up cancer to maximize surgical outcomes in oncology. FluoGuide's lead product, FG001, is designed to improve surgical precision by lighting up cancer intraoperatively. The improved precision has a dual benefit - it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision enhances the likelihood of complete cure and lower healthcare costs. FluoGuide has demonstrated that FG001 is both effective and well tolerated several phase II clinical trials. The lead indications of FG001 are aggressive brain cancer (glioblastoma) and oral head and neck cancer. FluoGuide has entered partnerships with leading MedTech companies with the aim of accelerating development and commercialization. FluoGuide is listed on Nasdaq First North Sweden under the ticker "FLUO".

For more information on FG001 or FluoGuide's uPAR technology platform, please visit our home page www.fluoguide.com

Attachments
Invitation to FluoGuide A/S (Nasdaq: FLUO) webcast on 27 November 2025

SOURCE: FluoGuide A/S



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/biotechnology/invitation-to-fluoguide-a%2fs-nasdaq-fluo-webcast-on-27-november-2025-1106200

© 2025 ACCESS Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.